CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Oak Hill takes SPAC track to Nasdaq with Roche asset in tow

IPO/OfferingrugonersenPositive
AI Analysis

Summary

Oak Hill Bio is pursuing a SPAC listing on Nasdaq while developing rugonersen, an antisense therapy for Angelman syndrome that was licensed from Roche in 2025.

Importance:6/10
Sentiment:
0.50
SPACIPOlicensing dealantisense therapyrare disease
Related Companies

Read the original article

Published by BioSpace on July 28, 2026 11:06 AM

Read Original